




Amendments to the Claims:

Please cancel Claims 50-55, 72 and 81 without prejudice or disclaimer; amend Claims 49, 56, 73-74, 82-84, 103, 114, 116, 118 and 127; and add new Claims 138-147 as set forth below.



1-48. (Canceled)

49. (Currently amended) A substrate for a protein kinase, wherein the substrate comprises a peptide and at least one fluorophore, wherein a fluorophore is attached to a serine, a threonine, or a tyrosine on at least one terminal end of the peptide, ~~and~~ wherein phosphorylation by the protein kinase of the terminal serine, the terminal threonine, or the terminal tyrosine to which the fluorophore is attached produces at least a 20% change in fluorescence intensity, and wherein the substrate is selected from the group consisting of:





wherein F is phenylalanine, K is lysine, and R is arginine; and wherein the LINKER is selected from the group consisting of N-methyl glycine, L-proline, D-proline,



50-55. (Canceled)


56. (Currently amended) A substrate for a protein kinase, wherein the substrate comprises:

a peptide comprising a serine, a threonine, or a tyrosine on a terminal end of the peptide;


at least one fluorophore, wherein a fluorophore is attached to the serine, the threonine, or the tyrosine on the terminal end of the peptide; and

a photolabile side chain attached to the serine, the threonine, or the tyrosine on the terminal end of the peptide, wherein the photolabile side chain blocks transfer of a phosphoryl group from adenosine triphosphate to a hydroxyl moiety of the serine, the threonine, or the tyrosine so that the substrate cannot be phosphorylated by a protein kinase until the photolabile side chain is removed from the substrate; [[,]] and

wherein the the photolabile side chain comprises the structure



or a fluorophore is attached to the peptide by a linker selected from the group consisting of



; and

wherein

- (i) the substrate is specific for a protein kinase subtype,
- (ii) the fluorophore is attached to the C-terminal end of the peptide,

(iii) a fluorophore is attached to each terminal end of the peptide,


(iv) a first fluorophore is attached to a terminal end of the peptide and a second fluorophore, with photophysical properties distinct from the first fluorophore, is attached to any nonterminal site on the peptide,

(v) the fluorophore is a 7-nitrobenz-2-oxa-1,3-diazole derivative,

(vi) the fluorophore is attached to the peptide by a linker selected from the group consisting of a carboxamide linker, an aminobenzoic acid linker, a sulfonamide linker, a urea linker, a thiourea linker, an ester linker, a thioester linker, an alkylamine linker, an arylamine linker, an ether linker, and a thioether linker, and/or

(vii) the substrate further comprises a carbohydrate, a lipid or a nucleic acid.

57. (Original) The substrate of claim 56, wherein the photolabile side chain comprises the structure



58. (Original) The substrate of claim 56, wherein the substrate comprises a serine with a photolabile side chain that blocks phosphoryl transfer.


59. (Original) The substrate of claim 58, wherein the substrate has the structure

Applicant: David S. Lawrence

Serial No.: 10/755,086

Filed: January 9, 2004

page 7 of 28



60. (Original) The substrate of claim 56, wherein after removal of the photolabile side chain, phosphorylation by a protein kinase of the terminal serine, the terminal threonine, or the terminal tyrosine to which the fluorophore is attached produces at least a 20% change in fluorescence intensity.

61. (Previously presented) The substrate of claim 60, wherein the change in fluorescence intensity when the substrate is phosphorylated by the protein kinase is an increase in fluorescence intensity.

62. (Previously presented) The substrate of claim 60, wherein the change in fluorescence intensity when the substrate is phosphorylated by the protein kinase is a decrease in fluorescence intensity.

63. (Previously presented) The substrate of claim 60, wherein phosphorylation of the substrate by the protein kinase produces at least a 70% change in fluorescence intensity.

64. (Original) The substrate of claim 63, wherein phosphorylation of the substrate by the protein kinase produces at least a 100% change in fluorescence intensity.

65. (Original) The substrate of claim 64, wherein phosphorylation of the substrate by the protein kinase produces at least a 150% change in fluorescence intensity.

66. (Original) The substrate of claim 65, wherein phosphorylation of the substrate by the protein kinase produces at least a 250% change in fluorescence intensity.

67. (Previously presented) The substrate of claim 56, wherein the substrate is specific for a protein kinase subtype.

68. (Original) The substrate of claim 67, wherein the substrate is specific for protein kinase C.

69. (Original) The substrate of claim 68, wherein the substrate is specific for isoforms α , β , and γ of protein kinase C.

70. (Withdrawn) The substrate of claim 67, wherein the substrate is specific for protein kinase A, protein kinase B, protein kinase D, protein kinase G, Ca^{+} /calmodulin-dependent protein kinase, mitogen-activated protein kinase, protein kinase mos, protein kinase raf, protein tyrosine kinase, tyrosine kinase abl, tyrosine kinase src, tyrosine kinase yes, tyrosine kinase fps, tyrosine kinase met, cyclin-dependent protein kinase, or cdc2 kinase.

71. (Previously presented) The substrate of claim 56, wherein the substrate further comprises a carbohydrate, a lipid or a nucleic acid.

72. (Canceled)

73. (Currently amended) The substrate of claim 56, ~~72~~, wherein the fluorophore is attached to the C-terminal end of the peptide.

74. (Currently amended) The substrate of claim 56, ~~72~~, wherein the fluorophore is attached to the N-terminal end of the peptide.

75. (Previously presented) The substrate of claim 56, wherein a fluorophore is attached to each terminal end of the peptide.

76. (Original) The substrate of claim 75, wherein fluorophores with distinct photophysical properties are attached to different terminal ends of the peptide.

77. (Previously presented) The substrate of claim 56, wherein a first fluorophore is attached to a terminal end of the peptide and a second fluorophore, with photophysical properties distinct from the first fluorophore, is attached to any nonterminal site on the peptide.

78. (Previously presented) The substrate of claim 56, wherein the fluorophore is a 7-nitrobenz-2-oxa-1,3-diazole derivative.

79. (Withdrawn) The substrate of claim 56, wherein the fluorophore is a fluorescein derivative.

80. (Withdrawn) The substrate of claim 56, wherein the fluorophore is selected from the group consisting of a dansyl derivative, an acridine derivative, an Alexa Fluor



derivative, a BODIPY derivative, an Oregon Green derivative, a Rhodamine Green derivative, a Rhodamine Red-X derivative, a Texas Red derivative, a Cascade Blue derivative, a Cascade Yellow derivative, a Marina Blue derivative, a Pacific Blue derivative, an AMCA-X derivative, and a coumarin derivative.

81. (Canceled)

82. (Withdrawn and Currently amended) The substrate of claim 56, ~~81~~, wherein the fluorophore is attached to the peptide by linker is a metal chelating linker.

83. (Currently amended) The substrate of claim 56, ~~81~~, wherein the fluorophore is attached to the peptide by a linker is selected from the group consisting of a carboxamide linker, an aminobenzoic acid linker, a sulfonamide linker, a urea linker, a thiourea linker, an ester linker, a thioester linker, an alkylamine linker, an arylamine linker, an ether linker, and a thioether linker.

84. (Withdrawn and Currently amended) The substrate of claim 56, ~~81~~, wherein the fluorophore is attached to the peptide by a linker is selected from the group consisting of N-methyl glycine, L-proline, D-proline,




85. (Canceled)

86. (Previously presented) A composition comprising the substrate of claim 56, and a carrier.

87. (Original) The composition of claim 86, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

88. (Original) A chemical compound selected from the group of compounds set forth in Table 3.

89. (Original) A chemical compound having the structure:




wherein the LINKER is selected from the group consisting of the following:

Applicant: David S. Lawrence


Serial No.: 10/755,086

Filed: January 9, 2004


page 12 of 28




a




b




c




d




e




f




g




h




i




j




k




l




m




n




o




p




q




r




s



t



u



v

no linker

w

90. (Original) A chemical compound having the structure:

fluorophore-LINKER-X-FRRRRK-amide (SEQ ID NO:3);

wherein F is phenylalanine; K is lysine; R is arginine; and X is serine, threonine, or tyrosine.

91. (Original) The chemical compound of claim 90, wherein the fluorophore is a 7-nitrobenz-2-oxa-1,3-diazole derivative.

92. (Withdrawn) The chemical compound of claim 90, wherein the fluorophore is a fluorescein derivative.



93. (Withdrawn) The chemical compound of claim 90, wherein the fluorophore is selected from the group consisting of a dansyl derivative, an acridine derivative, an Alexa Fluor derivative, a BODIPY derivative, an Oregon Green derivative, a Rhodamine Green derivative, a Rhodamine Red-X derivative, a Texas Red derivative, a Cascade Blue derivative, a Cascade Yellow derivative, a Marina Blue derivative, a Pacific Blue derivative, an AMCA-X derivative, and a coumarin derivative.

94. (Withdrawn) The chemical compound of claim 90, wherein the linker is a metal chelating linker.


95. (Original) The chemical compound of claim 90, wherein the linker is selected from the group consisting of a carboxamide linker, an aminobenzoic acid linker, a sulfonamide linker, a urea linker, a thiourea linker, an ester linker, a thioester linker, an alkylamine linker, an arylamine linker, an ether linker, and a thioether linker.

96. (Withdrawn) The chemical compound of claim 90, wherein the linker is


selected from the group consisting of N-methyl glycine, L-proline, D-proline,




97. (Original) The chemical compound of claim 90, wherein the linker is selected from the group consisting of the following:




a




b




c




d




e




f




g




h




i




j



k



l



98. (Original) The chemical compound of claim 90, wherein the chemical compound is a substrate for a protein kinase.

99. (Original) The chemical compound of claim 98, wherein the chemical compound is specific for protein kinase C.

100. (Original) The chemical compound of claim 99, wherein the chemical compound is specific for isoforms α , β , and γ of protein kinase C.

101. (Withdrawn) The chemical compound of claim 98, the chemical compound is specific for protein kinase A, protein kinase B, protein kinase D, protein kinase G, Ca^{2+} /calmodulin-dependent protein kinase, mitogen-activated protein kinase, protein kinase mos, protein kinase raf, protein tyrosine kinase, tyrosine kinase abl, tyrosine kinase

src, tyrosine kinase yes, tyrosine kinase fps, tyrosine kinase met, cyclin-dependent protein kinase, or cdc2 kinase.

102. (Original) The chemical compound of claim 90, wherein the chemical compound further comprises a carbohydrate, a lipid or a nucleic acid.

103. (Currently amended) A chemical compound comprising a peptide and at least one fluorophore, wherein a fluorophore is attached to a serine, a threonine, or a tyrosine on at least one terminal end of the peptide and wherein:

(i) the fluorophore is attached to the C-terminal end of the peptide,

(ii) a fluorophore is attached to each terminal end of the peptide,


(iii) a first fluorophore is attached to a terminal end of the peptide and a second fluorophore, with photophysical properties distinct from the first fluorophore, is attached to any nonterminal site on the peptide,

(iv) the fluorophore is a 7-nitrobenz-2-oxa-1,3-diazole derivative,


(v) the chemical compound is specific for protein kinase C,

(vi) the fluorophore is attached to the peptide by a linker selected from the group consisting of a carboxamide linker, an aminobenzoic acid linker, a sulfonamide linker, a urea linker, a thiourea linker, an ester linker, a thioester linker, an alkylamine linker, an arylamine linker, an ether linker, and a thioether linker,


(vii) the fluorophore is attached to the peptide by a linker selected from the group consisting of:




a




b




c




d




e




f




g




h




i




j




k




l




m




n




o




p




q




r




s



t



u



v

no linker

w

, and/or

(viii) the chemical compound further comprises a carbohydrate, a lipid or a nucleic acid.

104. (Original) The chemical compound of claim 103, wherein the fluorophore is attached to the C-terminal end of the peptide.

105. (Original) The chemical compound of claim 103, wherein the fluorophore is attached to the N-terminal end of the peptide.

106. (Original) The chemical compound of claim 103, wherein a fluorophore is attached to each terminal end of the peptide.

107. (Original) The chemical compound of claim 106, wherein fluorophores with distinct photophysical properties are attached to different terminal ends of the peptide.

108. (Original) The chemical compound of claim 103, wherein a first fluorophore is attached to a terminal end of the peptide and a second fluorophore, with photophysical properties distinct from the first fluorophore, is attached to any nonterminal site on the peptide.

109. (Original) The chemical compound of claim 103, wherein the fluorophore is a 7-nitrobenz-2-oxa-1,3-diazole derivative.

110. (Withdrawn) The chemical compound of claim 103, wherein the fluorophore is a fluorescein derivative.

111. (Withdrawn) The chemical compound of claim 103, wherein the fluorophore is selected from the group consisting of a dansyl derivative, an acridine derivative, an

Applicant: David S. Lawrence
Serial No.: 10/755,086
Filed: January 9, 2004
page 19 of 28



Alexa Fluor derivative, a BODIPY derivative, an Oregon Green derivative, a Rhodamine Green derivative, a Rhodamine Red-X derivative, a Texas Red derivative, a Cascade Blue derivative, a Cascade Yellow derivative, a Marina Blue derivative, a Pacific Blue derivative, an AMCA-X derivative, and a coumarin derivative.

112. (Original) The chemical compound of claim 103, wherein the fluorophore is attached to the peptide by a linker.


113. (Withdrawn) The chemical compound of claim 112, wherein the linker is a metal chelating linker.

114. (Currently amended) The chemical compound of claim 103, ~~112~~, wherein the fluorophore is attached to the peptide by a linker is selected from the group consisting of a carboxamide linker, an aminobenzoic acid linker, a sulfonamide linker, a urea linker, a thiourea linker, an ester linker, a thioester linker, an alkylamine linker, an arylamine linker, an ether linker, and a thioether linker.


115. (Withdrawn) The chemical compound of claim 112, wherein the linker is selected from the group consisting of N-methyl glycine, L-proline, D-proline,




116. (Currently amended) The chemical compound of claim 103, ~~112~~, wherein the fluorophore is attached to the peptide by a linker is selected from the group consisting of the following:




a




b




c




d




e




f




g




h




i




j



k



l



117. (Original) The chemical compound of claim 103, wherein the chemical compound is a substrate for a protein kinase.

118. (Currently amended) The chemical compound of claim 103, ~~117~~, wherein the chemical compound is specific for protein kinase C.

119. (Original) The chemical compound of claim 118, wherein the chemical compound is specific for isoforms α , β , and γ of protein kinase C.

120. (Withdrawn) The chemical compound of claim 117, wherein the chemical compound is specific for protein kinase A, protein kinase B, protein kinase D, protein kinase G, Ca^{2+} /calmodulin-dependent protein kinase, mitogen-activated protein kinase, protein kinase mos, protein kinase raf, protein tyrosine kinase, tyrosine kinase abl, tyrosine kinase src, tyrosine kinase yes, tyrosine kinase fps, tyrosine kinase met, cyclin-

Applicant: David S. Lawrence

Serial No.: 10/755,086


Filed: January 9, 2004

page 22 of 28

dependent protein kinase, or cdc2 kinase.

121. (Original) The chemical compound of claim 103, wherein the chemical compound further comprises a carbohydrate, a lipid or a nucleic acid.

122. (Original) A chemical compound having the structure



123. (Previously presented) A composition comprising a chemical compound of claim 89, and a carrier.

124-126. (Canceled)

127. (Currently amended) The substrate of claim 60, wherein the substrate comprises a metal ion chelator ~~induces the change in fluorescence intensity~~.

128. (Original) The substrate of claim 127, wherein the metal ion is a magnesium ion or a calcium ion.

129. (Previously presented) The chemical compound of claim 94, wherein a metal ion chelator induces a change in fluorescence intensity.

130. (Original) The chemical compound of claim 129, wherein the metal ion is a magnesium ion or a calcium ion.

131. (Original) The chemical compound of claim 129, wherein the change in fluorescence intensity is at least a 20% change in fluorescence intensity.

132. (Canceled)

133. (Original) The substrate of claim 81, wherein the linker comprises a turn to position the fluorophore in a location closer to the terminal serine, the terminal threonine or the terminal tyrosine than the location the fluorophore would occupy in the absence of a turn in the linker.

134. (Previously presented) The chemical compound of claim 89, wherein the linker comprises a turn to position the fluorophore in a location closer to the terminal serine, the terminal threonine or the terminal tyrosine than the location the fluorophore would occupy in the absence of a turn in the linker.

135-136. (Canceled)

137. (Previously presented) The composition of claim 123, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

138. (New) A composition comprising the substrate of claim 49, and a carrier.

139. (New) The composition of claim 138, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

140. (New) A composition comprising the compound of claim 88, and a carrier.

141. (New) The composition of claim 140, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

142. (New) A composition comprising the compound of claim 90, and a carrier.

143. (New) The composition of claim 142, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

144. (New) A composition comprising the compound of claim 103, and a carrier.

145. (New) The composition of claim 144, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.

146. (New) A composition comprising the compound of claim 122, and a carrier.

147. (New) The composition of claim 146, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier.